Table 1 Baseline clinical characteristics
Zotarolimus-eluting stent (n = 350) | Sirolimus-eluting stent (n = 345) | p | |
|---|---|---|---|
Age (years) | 64.8 (10.3) | 64.5 (10.4) | 0.71 |
Men | 271 (77.4%) | 269 (78.0%) | 0.86 |
Family history of coronary artery disease | 154 (44.9%) | 141 (41.6%) | 0.38 |
Current smokers | 94 (28.1%) | 100 (30.9%) | 0.44 |
Diabetes mellitus | 44 (12.6%) | 52 (15.1%) | 0.34 |
Body mass index (kg/m2) | 27.5 (5.6) | 27.2 (4.6) | 0.44 |
Hypertension | 203 (59.0%) | 178 (52.7%) | 0.10 |
Hypercholesterolemia | 243 (70.4%) | 233 (68.7%) | 0.63 |
Previous myocardial infarction | 130 (37.7%) | 129 (38.4%) | 0.84 |
Previous percutaneous coronary intervention | 72 (20.9%) | 48 (14.2%) | 0.02 |
Previous coronary artery bypass surgery | 16 (4.6%) | 18 (5.3%) | 0.68 |
Charlson comorbidity score | 0.35 | ||
0 | 232 (66.3%) | 211 (61.2%) | |
1 or 2 | 98 (28.0%) | 109 (31.6%) | |
3 or more | 20 (5.7%) | 25 (7.2%) | |
Indication for intervention | 0.19 | ||
Stable angina pectoris | 195 (55.7%) | 177 (51.3%) | |
ST-segment elevation myocardial infarction | 13 (3.7%) | 16 (4.6%) | |
Unstable angina pectoris or non-ST-segment elevation myocardial infarction | 129 (36.9%) | 146 (42.3%) | |
Other | 13 (3.7%) | 6 (1.7%) |